|
|
 |
|
Viewing report
|
|
|
|
Pro-Pharmaceuticals, Inc
The Research Works, Dec 2010, Pages: 40
Equity research report on Pro-Pharmaceuticals, Inc, a developer of galectin-targeting polysaccharide compounds for the treatment of cancer and fibrosis. Includes a survey of the cancer market and top drugs, the company's technology, and business and financial analysis.
Company Description
Pro-Pharmaceuticals, Inc. (“Pro” or the “Company”) is pioneering the use of non-toxic carbohydrates (polysaccharides) for the treatment of cancer and fibrosis. Pro’s technology uses a unique mechanism of blocking Galectins, which are found on all solid tumors and are involved in fibrosis. The Company has advanced a cancer drug candidate through Phase II clinical trials.
Key Topics Include:
Introduction to Pro-Pharmaceuticals’ Drugs
Survey of the Cancer Market
Exhibit: Incidence of and Fatalities from Common Cancers
- Introduction to Chemotherapy
- Exhibit: Branded Chemotherapy Drugs: Mechanisms and Side-effects
- Exhibit: Popular Chemotherapy Drug Annual Sales
Fluorouracil, the Complementary Cancer Drug in Pro-Pharma’s Initial Market
- Manufacturers, Mechanism, Applications
- Dosage, Treatment Cycle, Side-Effects
- Sales
Pro-Pharma’s Top Drug Candidate for Cancer, DAVANAT®
- Description and Mechanism
- Overview of DAVANAT®’s Clinical Trials
- Pricing Considerations for DAVANAT®
Pro-Pharma’s Pre-Clinical Fibrosis Drug Candidate, PRO-GR
- Lab Results and Target Market
Recent Developments and Milestones
Financials
- Income Statements
- Balance Sheet
- Cash Flow Statements
Stock Valuation
- Exhibit: Hypothetical Market-Sizing Model for DAVANAT®
- Factors Effecting Commercialization
- Comparable Company Analysis
- Investment Summary
Management and Board of Directors
Appendix A
- Details of Phase I Trial
- Details of Phase II Clinical Trials
Appendix B: Market Data for Top Chemotherapy Drugs
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
